Valuation: Libra Infusions Limited

Market Cap 1.53B 188B 1.34B 1.26B 1.15B 2.15B 147B 2.15B 15.08B 5.81B 74.84B 5.76B 5.63B 242B P/E 2016
131x
P/E 2017 107x
Enterprise Value 2.43B 298B 2.12B 1.99B 1.82B 3.4B 233B 3.41B 23.88B 9.2B 118B 9.12B 8.92B 382B EV / Sales 2016
6.88x
EV / Sales 2017 6.34x
Free-Float
99%
Yield 2016
0.41%
Yield 2017 0.57%
1 day-0.14%
1 week+2.98%
Current month-4.40%
1 month-6.23%
3 months-10.19%
6 months-12.69%
Current year-9.54%
1 week 563.1
Extreme 563.1
580
1 month 550.1
Extreme 550.1
629
Current year 547.1
Extreme 547.1
739
1 year 547.1
Extreme 547.1
805
3 years 521.33
Extreme 521.333333
1,146.67
5 years 435
Extreme 435
1,146.67
10 years 238.33
Extreme 238.333332
1,146.67
Manager TitleAgeSince
Chief Executive Officer - 01/02/1976
Director of Finance/CFO - -
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member - 20/06/2011
Chairman - 12/02/2013
Director/Board Member - 20/06/2011
Change 5-day change 1-year change 3-year change Capi.($)
-0.14%+2.98%-24.87%+3.73% 10.52M
+1.04%+2.34%+54.91%+111.75% 1,038B
-0.19%+1.18%+52.94%+66.69% 649B
+0.20%+1.04%+18.88%+72.38% 467B
-0.84%+0.58%+33.79%+45.43% 355B
-0.06%+2.04%+18.17%+26.34% 269B
+0.38%+4.08%+9.65%+14.16% 260B
+1.95%+3.06%+37.75%+45.93% 213B
-1.26%-6.72%-32.84%-59.88% 176B
+0.30%+2.83%+31.97%+100.03% 187B
Average +0.25%+1.07%+20.04%+42.66% 361.51B
Weighted average by Cap. +0.54%+1.47%+35.35%+65.82%

Financials

2016 2017
Net sales 238M 29.25B 208M 196M 178M 334M 22.82B 334M 2.34B 903M 11.62B 895M 875M 37.5B 244M 30B 213M 201M 183M 342M 23.4B 343M 2.4B 926M 11.92B 918M 897M 38.47B
Net income 5.82M 715M 5.07M 4.78M 4.35M 8.16M 558M 8.17M 57.24M 22.06M 284M 21.86M 21.38M 917M 6.09M 747M 5.31M 5M 4.55M 8.53M 583M 8.54M 59.84M 23.07M 297M 22.86M 22.35M 958M
Net Debt 880M 108B 767M 722M 658M 1.23B 84.26B 1.23B 8.65B 3.33B 42.92B 3.3B 3.23B 139B 894M 110B 780M 734M 669M 1.25B 85.66B 1.26B 8.79B 3.39B 43.63B 3.36B 3.28B 141B
Logo Libra Infusions Limited
Libra Infusions Ltd is a Bangladesh-based company engaged in the manufacturing of Intravenous (I.V.) fluid. The Company's products include LIBOTT, LIBOTT-10, LIBOTT-25, LIBOTT-S, LIBOTT-S JR, NORMASOL, BABY SALINE, DIASOL, HARTSOL, LIBRAZOL, LIBRACIN, LIBOTT-M, LIBRACIN-400, and LIBRET. Its products are used in medical situations involving diarrheal disease, surgical operation, loss of blood, weakness and hospitalization in general. LIBOTT is used for rehydration in a time of water deficit, general weakness and post-surgical intervention. LIBOTT-10 is used for the treatment of jaundice, general weakness, eclampsia and pre-eclampsia. LIBOTT-25 is used in the emergency treatment of severe hypoglycemia. LIBOTT-S is used for rehydration during general weakness, water deficiency along with sodium, diuresis, intoxication and post-surgical intervention. LIBOTT-S JR fulfills the water deficit along with low deficiency of sodium chloride and supplies energy for growing children.
Employees
699
Date Price Change Volume
21/09/26 BDT 573.70 -0.14% 1,938
20/09/26 BDT 574.50 +0.09% 1,850
17/09/26 BDT 574.00 +1.38% 2,599
16/09/26 BDT 566.20 -0.04% 907
15/09/26 BDT 566.40 +1.67% 2,108
  1. Stock Market
  2. Stocks
  3. LIBRAINFU Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!